Provided by Tiger Trade Technology Pte. Ltd.

Scinai Immunotherapeutics Ltd.

0.7400
+0.02623.67%
Post-market: 0.6801-0.0599-8.09%19:55 EDT
Volume:337.85K
Turnover:241.64K
Market Cap:2.62M
PE:-0.21
High:0.7600
Open:0.6989
Low:0.6856
Close:0.7138
52wk High:6.18
52wk Low:0.4549
Shares:3.54M
Float Shares:3.13M
Volume Ratio:0.01
T/O Rate:10.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5578
EPS(LYR):5.95
ROE:-91.89%
ROA:-37.60%
PB:1.06
PE(LYR):0.12

Loading ...

Company Profile

Company Name:
Scinai Immunotherapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
31
Office Location:
Jerusalem BioPark,2nd floor,Hadassah Ein Kerem Campus,Jerusalem,Israel
Zip Code:
- -
Fax:
972 8 930 2531
Introduction:
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Directors

Name
Position
Amir Reichman
Chief Executive Officer and Director
Mark Germain
Chairman of the Board
Adi Raviv
Director
Jay Green
Director
Samuel Moed
Director
Yael Margolin
Director

Shareholders

Name
Position
Amir Reichman
Chief Executive Officer and Director
Elad Mark
Chief Operating Officer
Uri Ben Or
Chief Financial Officer